ORANGEBURG, N.Y., April 20, 2009 (GLOBE NEWSWIRE) -- Spectrum Dynamics announced today that it has recently closed on a round of new financing. The financing came from institutional and private investors, and will provide the necessary capital to realize both its short and long term strategic plans.
"This new capital, coupled with the recent approvals to sell the D-SPECT in Canada and Europe will provide Spectrum with a significant platform for growth," stated James Haisler, CEO of Spectrum Dynamics.
"Spectrum Dynamics has primarily focused on only a small component of the U.S. market with a very specific product. Having these funds will allow the company to increase its sales footprint both in and outside the U.S. as well as bring new products to market that will appeal to a broader range of customers," said Josh Gurewitz, VP of Sales and Marketing.
For more information about the D-SPECT, please visit Spectrum Dynamics at booth #512 at the upcoming Society of Nuclear Medicine annual meeting or online at www.spectrum-dynamics.com.
About Spectrum Dynamics
Spectrum Dynamics, with offices in New York, California and research and development facilities in Haifa, Israel, is a pioneering medical device company focused on personalized molecular imaging and applications. Spectrum Dynamics will revolutionize the practice of nuclear cardiology, and eventually all nuclear medicine applications, by dramatically enhancing workflow and providing new clinical applications not possible with conventional technology. Additional information can be found at www.spectrum-dynamics.com.
Forward-Looking Statements
This press release contains forward-looking statements about Spectrum Dynamics, including projections about its business and the nuclear medicine market. These forward looking statements are not guarantees of future performance and actual results could differ.